WTA: Chris Evert receiving treatment for cancer recurrence

Date:

Share post:


Tennis great Chris Evert is dealing with a recurrence of ovarian cancer, and treatments will keep her off television broadcasts of the upcoming Australian Open.

“While this is a diagnosis I never wanted to hear, I once again feel fortunate that it was caught early,” Evert said in a statement issued through ESPN, for whom she is an analyst. “Doctors found cancer cells in the same pelvic region. All cells were removed, and I have begun another round of chemotherapy.

“I will be unable to join my colleagues when ESPN makes its return to Melbourne for the Australian Open next month. But I’ll be ready for the rest of the Grand Slam season!

“I encourage everyone to know your family history and advocate for yourself. Early detection saves lives. Be thankful for your health this holiday season.”

Evert, 68, was first diagnosed with ovarian cancer in 2021.

Evert captured 18 career Grand Slam singles titles: two at the Australian Open, seven at the French Open, three at Wimbledon and six at the U.S. Open. She added three major doubles championships and helped the United States win the Fed Cup eight times.

After a pro career that ran from 1972-89, Evert was enshrined in the International Tennis Hall of Fame in 1995.

–Field Level Media

spot_img

Related articles

WTA: WTA roundup: Elise Mertens cruises in Singapore

No. 2 seed Elise Mertens of Belgium needed just 55 minutes to beat Taylor Townsend 6-1, 6-0 in...

ATP: Arthur Rinderknech goes the distance in Montpellier opener

No. 7 seed Arthur Rinderknech beat fellow Frenchman Harold Mayot 7-6 (2), 2-6, 6-1 to move on at...

WTA: WTA roundup: Emma Raducanu shown early exit in Singapore

Cristina Bucsa of Spain rallied to eliminate No. 7 seed Emma Raducanu of Great Britain 5-7, 7-5, 7-5...

ATP: Arthur Cazaux defeats Stan Wawrinka in hometown of Montpellier

Arthur Cazaux of France took down Swiss wild card Stan Wawrinka 6-4, 6-3 in the first round of...

FREE

Get the most important breaking news and analyses for Free.

Thank you for subscribing

Something went wrong.